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ABSTRACT    
 
Background:  A few studies have observed reduced breast cancer mortality in women 
who used hormone therapy (HT) prior to diagnosis. Due to the high prevalence of 
hormone use, it is important to establish whether these preparations are related to 
breast cancer mortality.  
Methods:  To evaluate the influence of prediagnostic use of HT on breast cancer 
mortality, a prospective cohort of 12,269 women aged  50 years or more diagnosed with 
incident invasive breast cancer and residents of Wisconsin, Massachusetts, or New 
Hampshire, US were enrolled in three phases beginning in 1988. They were followed for 
death until December 31, 2004 using the National Death Index.  
Results:  During an average 9.6 years of follow up, 1614 deaths from breast cancer 
were documented. Cumulative mortality from breast cancer was lower among HT users 
compared to nonusers.  Survival varied by type and duration of HT prior to diagnosis, a 
reduced risk of death from breast cancer was associated with ever use of estrogen-
progestin (EP) preparations (HRR 0.71 (0.57-0.88) and with ≥5 years of EP use (0.54; 
0.38-0.76)  No association was observed for women former or current users of 
estrogen-only preparations.   
Conclusions:  Although use of combined EP preparations increases breast cancer risk, 
in this study, use of these hormones before diagnosis was associated with reduced risk 
of death after a breast cancer diagnosis. Survival was best among recent and long-term 
users.   
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INTRODUCTION 
Compelling evidence demonstrates that hormone therapy (HT) use, particularly 
formulations containing progestins, increases breast cancer incidence (1, 2).  However, 
reduced breast cancer mortality has been observed among women using HT prior to 
breast cancer diagnosis in several studies (3-11).  It is not yet clear whether 
associations with survival are attributable to the hormones themselves, or to the 
healthier profiles, screening habits, or treatment choices of women prescribed 
hormones (8-10).  An inverse relation between HT use and breast cancer mortality 
might also be explained by more favorable tumor profiles, and therefore improved 
prognosis, among HT users compared with non-users (11-14). 
A substantial proportion of women in the U.S. have used HT in their lifetimes, 
including about half of postmenopausal U.S. women aged 50-69 years (15, 16).  Given 
the large number of women with a history of HT use, an established risk factor for 
breast cancer incidence, it is important to establish whether the use of these 
preparations is also related to survival.  Previous studies have been limited by modest 
sample sizes, restriction to high-risk groups, and inability to evaluate the characteristics 
of users and subtypes of tumors (3-6, 11, 17-19).  We therefore examined the relation 
between prediagnostic HT use and mortality (from breast cancer and all causes) in a 
study that addressed these limitations, using data from a well-characterized cohort of 
12,269 women with incident invasive breast cancer (20, 21).  
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MATERIALS AND METHODS 
Collaborative Breast Cancer Study Cohort
 
The Collaborative Breast Cancer Study Cohort began in 1988 as a multi-site 
population-based case-control study of risk factors for breast cancer (20, 21).  A total of 
18,269 women with incident invasive breast cancer were enrolled during three 
successive phases of this study.  Age eligibility varied over the course of the study 
which included women aged 20-74 years in phase 1 (1988-91), aged 50-79 years in 
phase 2 (1992-95) and aged 20-69 years in phase 3 (1997-2001). Approximately 81% 
of eligible case women participated in the case-control study.   
 
Ascertainment of Exposure  
All subjects completed a structured telephone interview that included detailed 
information on prediagnosis use of HT, including formulation, routes of administration, 
frequency for each episode of use, and information on other breast cancer risk factors, 
specifically reproductive and menstrual history, consumption of specific foods and 
beverages including alcohol, physical activity, height and weight history, medication use, 
and personal and family history of cancer.  Women were asked to report exposures 
occurring in the year prior to diagnosis, approximately two years prior to interview.  
Format of the questions on HT use varied slightly depending on period of data 
collection; all versions after 1989 elicited a standard history of HT, including type, 
duration, age started and time since last use.  
Clinical information obtained from state cancer registries included date of 
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diagnosis, extent of disease (local, regional and distant) and histology (22).  In 
Wisconsin only, information was available on the first course of treatment (surgery, 
chemotherapy, radiation, and hormonal treatment). 
 
Population for Analysis 
The analysis was limited to women aged 50 years or more at the time of 
diagnosis, for consistency with all three studies (n=14,462).  The following women were 
excluded: 1,407 were interviewed before complete HT questions were included in the 
interview; 662 had missing information on HT usage; 116 used hormones before age 40 
or surgical menopause, and 8 women were lost during follow up.  Thus, 12,269 women 
were included in the analysis. 
 
Identification of Deaths 
Deaths were ascertained up to December 31, 2004 using automated searches of 
the National Death Index (23).  The underlying cause of death on the death certificate 
was assigned according to the International Classification of Diseases, Ninth Revision 
(ICD-9) (though 1998) (24) and ICD-10 (1999-2000) (25). We considered both death 
from breast cancer (ICD-9 codes 174-174.9 and ICD-10 codes C50.0-C50.9), and all-
cause mortality.   
 
Statistical Analysis 
Survival time was calculated as the number of months from date of diagnosis to 
date of death, or December 31, 2004 for surviving women.   Annual age-adjusted 
 
 6
mortality rates were computed according to length of HT use (26).  Women were 
classified as ever/never having used HT; women who had ever used HT were then 
further classified by current use or former use of HT at the time of diagnosis, with 
current use defined as HT use in the year prior to breast cancer diagnosis.  HT 
exposure by type of preparation was assessed as estrogen only (“E-only”) or combined 
estrogen and progestin only (“EP-only”) when women had used only one of these HT 
types; otherwise, HT was assessed as use of any preparation.  We also examined the 
duration (<5, > 5 years) and timing (current, former) of use. To determine the risks of 
dying from breast cancer according to HT (never, E-only, EP- only and by recency of 
use), we used life table techniques to calculate estimated cumulative incidence of 
death, a statistical method that accounts for the presence of competing risk (e.g., death 
from causes other than breast cancer) (27). 
Cox proportional hazards regression was used to estimate the adjusted hazard 
rate ratio (HRR), interpreted here as a rate ratio, and corresponding 95% confidence 
intervals (95% CI) for death according to categories of HT use (28). All regression 
models were stratified on study center, year of interview, and exact age at diagnosis.  
Potential confounders included in multivariate models were body mass index (BMI, 
kg/m2) in quartiles, history of mammography screening, time from date of diagnosis to 
interview, and menopausal status.  Women were classified as postmenopausal if they 
reported having a natural menopause or hysterectomy with bilateral oophorectomy at 
the reference date.  Women with hysterectomy without bilateral oophorectomy were 
considered postmenopausal if they had reached the age at which natural menopause 
occurred in 90% of the controls. All reported P values are two sided and statistical 
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significance was evaluated at 0.05.  All analyses were performed using SAS version 9.1 
(SAS Institute, Inc., Carey, NC). 
 
RESULTS 
Women were followed, on average, for 9.6 years from diagnosis.  A total of 3,653 
deaths were documented, including 1,614 from breast cancer. Women who used HT 
were younger, of lower BMI, were more likely to have a history of mammographic 
screening, and more likely to be diagnosed with a local stage of disease than nonusers 
(Table 1).  
Cumulative breast cancer mortality differed depending on whether the woman 
had ever used HT (Figure 1), with the lowest cumulative mortality found among women 
using EP (Figure 2).  Cumulative breast cancer mortality was also lower among long 
term users compared to short term users of HT, with the lowest cumulative mortality 
among long-term users of EP-only (data not shown). 
Overall, there was a significant inverse association between ever having used 
any HT and breast cancer mortality (adjusted HRR 0.86, 95% CI 0.76-0.96; Table 2).  
This multivariate HRR associated with ever use of HT was attenuated from the crude 
HRR of 0.78, suggesting appreciable confounding by body mass index, history of 
mammography, and other covariates in the model.  This reduction in mortality was 
found most strongly in current users of HT (adjusted HRR 0.82, 95% CI: 0.71-0.95).  
HRR’s for current users after additional adjustment for stage of disease (HRR 0.85, 
95% CI: 0.73-0.98) changed only slightly, suggesting little evidence of further 
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confounding by extent of disease.  For ever use of HT, there was a suggestion that 
breast cancer specific mortality was lower for EP-only (HRR = 0.71) than for estrogen-
only (HRR = 0.88), however, these were not statistically significantly different.  
For women using EP-only, breast cancer mortality varied according to duration 
and timing of use (Table 2).  A significant reduction in breast cancer mortality 
associated with HT use was observed for current users of EP-only (HRR:  0.65; 95% CI: 
0.51-0.84) compared to never users of HT, and the greatest benefit was observed for 
long-term users (>5 years, HRR: 0.54; 95% CI: 0.38-0.76).  In contrast, there was no 
statistically significant relation between former EP use and breast cancer mortality. For 
users of E-only preparations, there were no statistically significant associations between 
breast cancer mortality and current, former or duration of use.  Differences between E-
only and EP-only were significantly different for both current (p=0.03) and long-term 
users (p=0.01).  
Results stratified by extent of disease showed lower HRR’s among women with 
breast cancer diagnosed at a regional stage of disease than at a local stage (Table 2), 
although HRR’s were not statistically different by stage.  Among women diagnosed at a 
regional stage, HRR’s were strongly and significantly lower for both long-term users of 
EP-only (HRR 0.46; 95% CI: 0.27-0.81) and women currently using EP-only (HRR 0.53; 
95% CI: 0.37-0.78).  
Breast cancer cases diagnosed with lobular disease (n=1,159) showed similar 
overall associations between current and EP-only HT use and breast cancer mortality, 
with two notable exceptions (data not shown).  Current users of E-only with lobular 
disease experienced a halving in breast cancer mortality (HRR: 0.50; 95% CI: 0.27-
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0.94).  In contrast, among women with lobular disease, former EP-only users 
experienced a three-fold higher breast cancer mortality (95% CI: 0.93-9.32).  Although 
few EP-only former users had breast cancer as an underlying cause of death, this 
elevated risk contrasts with the low HRR’s seen above. 
The associations with current HT were consistent according to age at diagnosis 
(<60 years, ≥60 years, p=0.58) and BMI (<25.7 kg/m2, ≥25.7 kg/m2, p=0.67). The 
results of analyses stratified by state (NH, WI, MA) were also similar to the combined 
results, with no significant heterogeneity observed.  In a sub-analysis of Wisconsin 
women, where first course of treatment was available, treatment-adjusted results were 
similar to results unadjusted for treatment (data not shown). 
Death from all causes was also significantly lower in current users of HT 
(adjusted HRR 0.73; 95% CI: 0.66-0.81) and former HT users (adjusted HRR 0.86; 95% 
CI: 0.78-0.96; Table 3).  Both current users of EP-only (HRR 0.57; 95% CI: 0.47-0.70) 
and E-only (HRR 0.78; 95% CI: 0.69-0.89) displayed lower risks of all-cause mortality; 
notably the difference in HRR’s was statistically significant (p=0.02).  Inverse relations 
with mortality also differed by type of preparation (p=0.004) among long-term users of 
EP-only (HRR 0.50; 95% CI: 0.38-0.66) compared with E-only (HRR 0.81, 95% CI: 
0.72-0.91). Former users of E-only experienced a modestly lower risk (HRR 0.84, 95% 
CI: 0.75-0.95).  Increasing time since last use did not appear to be significantly 
associated with this inverse relation for either HT type (Pcontinuous >0.05, data not shown). 
  
  
DISCUSSION 
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The extent to which specific HT use influences the risk of mortality among breast 
cancer cases had been largely unknown, and no prior research has investigated 
whether or not this risk varies by either patient or tumor characteristics. In this large 
population-based cohort of women with breast cancer, current use of HT was 
associated with a moderately lower breast cancer specific mortality when compared to 
never use of these preparations. Mortality was lowest among current and long-term 
users of combined EP therapy.  The present results provide the strongest evidence to 
date that HT use is associated with the subsequent development of less aggressive 
breast cancers through mechanisms that are not yet fully clear.   
Evidence is limited on the relationship between HT use before breast cancer 
diagnosis and mortality from this disease.  This and other studies evaluated self-
reported HT use before the diagnosis of invasive breast cancer (3-5). Only one showed 
a statistically significant lower risk of the association of pre-diagnostic HT use with case 
fatality in a cohort (n= 2,614 women) with breast cancers assembled in a large breast 
cancer screening program (5).  After adjustment for age, race, BMI, tumor size, and 
number of positive lymph nodes, women using HT at the time of diagnosis experienced 
approximately half the risk of dying of breast cancer in both node-negative and node-
positive disease, although this effect waned with increasing time since diagnosis. These 
authors reported that the inverse association was no longer apparent after 4 years for 
node-positive disease and 12 years for node-negative disease, and thus this 
association may reflect residual confounding due to screening for node-positive 
disease, but this is less likely for node-negative disease, given the prolonged protection 
conferred. Limitations of the study are that the results were not stratified by type of HT, 
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and other relevant personal and tumor characteristics.   
In an earlier study, Bergkvist et al compared a group of 261 cases of breast 
cancer that had taken E-only prior to diagnosis with 6627 breast cancer cases identified 
through a population cancer registry whose estrogen exposure status was unknown (3). 
 After consideration of mortality attributable to competing risks of death, the relative 
survival rate among previous users of HT was suggestively higher when compared with 
the general cancer registry cases with a greater reduction in breast cancer mortality in 
uses of EP.  Other investigators have reported decreased all-cause mortality among 
women with breast cancer who had used HT , though these studies made no 
adjustment for competing risks of death, potentially leading to bias (4, 6, 11, 29).   
Studies have also generally shown lower breast cancer mortality with HT use in 
women initially without cancer, although in one study the mortality effects observed with 
HT use appear to wane over time, with increased breast cancer mortality observed 
among women using HT for 10 years of more (30).  Because studies have consistently 
indicated a modestly increased risk of developing breast cancer in HT users (31-34), 
these results suggest that breast cancers that develop in HT users may be associated 
with a less aggressive course than breast cancers that develop in nonusers (9, 30, 35-
43).   A further reason for lower case-fatality may be that the cancers developing in 
women using HT are selected to be more hormonally responsive.  Thus, with 
termination of the promoting factor at diagnosis (HT use) and the use of anti-estrogen 
treatment, now standard of care, these tumors would be expected to be particularly 
responsive.   
It has been suggested that the reduction in breast cancer mortality associated 
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with HT use is attributable to an earlier stage at diagnosis (3, 19), which may be due to 
a higher likelihood of screening among HT users (surveillance bias) (5) or the tendency 
for women who develop a serious illness to stop taking HT (healthy estrogen-user 
effect) (44), rather than a modifying effect of hormone use on tumor biology.  It has 
been well-documented that HT users are likely to be screened more aggressively than 
non-users (45) and have cancers that are diagnosed at an earlier stage (46), despite 
evidence that use of postmenopausal hormones reduces both sensitivity and specificity 
of screening mammograms (47).  However, even in analyses that adjust for screening, 
cancers that develop in HT users tend to be smaller (11, 19), of lower grade (48), have 
fewer positive maxillary lymph nodes (11, 19, 49), lower tumor cell proliferation rate (50, 
51), and have other clinically more favorable features (14, 49).  Yet, in the Women’s 
Health Initiative (WHI) randomized trial of the combined EP regimen, the rate of incident 
metastatic breast cancer was similar regardless of HT assignment (2). 
It may also be relevant to consider an effect of HT’s on tumor growth after 
diagnosis.  Although rare, HT use initiated after diagnosis of breast cancer has been 
shown to have a beneficial (5, 17, 52) or neutral (18) association with survival, and there 
has been no observed improvement in survival associated with duration of use or route 
of administration (oral or vaginal cream) (52).   
In our study, we found better breast cancer survival among women who used 
combined EP therapy before diagnosis.  Widespread use of combined EP preparations 
began in the 1980’s (53) and most earlier mortality studies evaluated the use of E-only 
formulations.  Two previous studies have reported more favorable prognostic profiles 
associated with combined estrogen-progestin therapy relative to other types of HT.  
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Magnusson et al. found that women receiving a combined EP regimen were less likely 
to have tumors >20mm in diameter, but to have axillary lymph node dissemination, and 
poorly differentiated, or aneuploid tumors at diagnosis (19).  Daling et al. observed that 
the tumors of users of continuous combined hormonal therapy (relative to E-only 
therapy or sequential combined therapy) were more likely to be estrogen receptor and, 
progesterone receptor positive (54), features that are associated with better prognosis. 
(14) Thus, our observation of reduced mortality among users of combined HT might be 
expected, based upon the generally favorable profiles of the tumors occurring among 
women using HT compared to the tumors developing in non-users, or users of other 
regimens.  
Our confidence in these study results is enhanced by the large sample size, 
mature follow-up, and availability of comprehensive information on tumor stage and 
other covariates associated with breast cancer mortality.  Arising from a population-
based study with high response rates, the cohort reflected the spectrum of breast 
cancer as it occurs in the population.  However, some limitations should be considered 
when interpreting our results.  This evaluation was based upon HT use before 
diagnosis, approximately two years prior to interview. Participants were not followed-up 
for changes in HT practices after breast cancer diagnosis, except on a subset of the 
population that participated in a study of post-diagnosis diet and other factors, including 
HT, in relation to breast cancer survival.  In this actively followed sub-group, few women 
(4.5%) reported use of HT—which has generally not been recommended after breast 
cancer diagnosis (55).  Thus, the uncommon use of post diagnostic HT is unlikely to 
have biased our results. However, other exposures sustained or initiated after diagnosis 
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may affect survival.  Unmeasured post-diagnosis characteristics of HT users, such as 
changes in weight and physical activity, could influence the observed differences in 
survival according to HT use.   
Screening is a particularly important covariate affecting survival. In our population 
HT was strongly associated with mammography:  only 10% of HT users had never been 
screened compared with 30% of never users.  As screening history was self-reported by 
each woman, residual confounding by mammography is a possibility.  Women who use 
HT, especially combined EP preparations, are more likely to have greater breast density 
than non-users (56).  Increased breast density is a clinically significant predictor of 
breast cancer risk (57), and HT users with increased breast density may experience 
worse prognosis (58, 59). However, only about 20-35% of women initiating HT 
experience these changes in breast density (60).  
We were unable to consider the ER/PR status of tumors in our analysis.  As a 
common phenotype of breast cancer tumors, the inability to control for receptor status is 
unlikely to overestimate our estimates of survival by HT use; rather, the combination of 
all tumor types increases the heterogeneity of our sample and may attenuate our results 
if HT use is related to survival only among those with tumors expressing ER/PR.  
However, since ER/PR positivity increases with increasing age (61); and  our sample 
was postmenopausal, most women’s tumors would have been hormone receptor 
positive.  
In summary, we found that use of HT prior to diagnosis in a large population-based 
cohort of women with breast cancer was associated with improved breast cancer 
survival.  Survival was best among recent and long-term users, and among women 
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using combination regimens including EP.  The better breast cancer survival in users of 
HT prior to diagnosis is unlikely to be attributable to differences in screening, stage, or 
other measured characteristics related to HT use and breast cancer mortality.   
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TABLE 1.  Baseline characteristics of study subjects by postmenopausal hormone use. 
        
    HT non-users HT ever users 
   E-only E+P 
  (N=8071) (N=2258) (N=1340) 
Characteristic N (%) N (%) N (%) 
Age at Diagnosis      
  50-54  1342 (16.6) 335 (14.8) 379 (28.3) 
  55-59  1116 (13.8) 445 (19.7) 479 (35.8) 
  60-64  1586 (19.6) 497 (22.0) 324 (24.2) 
  65-69  2079 (25.8) 517 (22.9) 132 (9.9) 
  70-74  1332 (16.5) 344 (15.2) 22 (1.6) 
  75-79  616 (7.6) 120 (5.3) 4 (0.3) 
      
Extent of Disease/Stage     
  Local  4836 (59.9) 1470 (65.1) 914 (68.2) 
  Regional  2191 (27.1) 539 (23.9) 322 (24.0) 
  Distant 249 (3.1) 36 (1.6) 13 (1.0) 
  Unstaged 795 (9.9) 213 (9.4) 91 (6.8) 
      
Histologic Type     
  Lobular 729 (9.0) 219 (9.7) 155 (11.6) 
  Non-lobular 7342 (91.0) 2039 (90.3) 1185 (88.4) 
      
Menopausal Status     
  Postmenopausal 7109 (88.1) 2094 (92.7) 1154 (86.1) 
  Premenopausal 807 (10.0) 35 (1.6) 115 (8.6) 
  Unknown 155 (1.9) 129 (5.7) 71 (5.3) 
      
Body Mass Index     
  Less than 22.8 1724 (21.4) 577 (25.6) 409 (30.5) 
  22.8-25.5 1878 (23.3) 565 (25.0) 348 (26.0) 
  25.6-29.1 2014 (25.0) 574 (25.4) 314 (23.4) 
  Unknown 291 (3.6) 49 (2.2) 24 (1.8) 
      
Regular History of Mammography Screening    
  Yes  2293 (28.4) 249 (11.0) 40 (3.0) 
  No  5064 (62.7) 1842 (81.6) 1263 (94.3) 
  Unknown  714 (8.9) 167 (7.4) 37 (2.8) 
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TABLE 2. Breast cancer mortality of women by use of hormone therapy prior to breast cancer diagnosis for all women and stratified by stage of disease.  
 All Women  Localized  Regional  
 (n=12269) (n=7601) (n=3270) 
Hormone Therapy 
Number 
of 
Deaths 
Rate 
ratio*  (95%CI) 
Multivariate 
rate ratio*† (95%CI) 
Number 
of Deaths 
Multivariate 
rate ratio*† (95%CI) 
Number of 
Deaths 
Multivariate 
rate ratio*† (95%CI) 
            
Never‡ 1186 1.00 reference 1.00 reference 339 1.00 reference 605 1.00 reference 
Ever HT 428 0.78 0.70-0.87 0.86 0.76-0.96 165 1.14 0.93-1.39 205 0.82 0.69-0.97 
  Former 163 0.86 0.73-1.02 0.91 0.77-1.08 57 1.03 0.77-1.37 85 1.00 0.79-1.26 
  Current 265 0.73 0.63-0.84 0.82 0.71-0.95 108 1.22 0.96-1.56 120 0.71 0.57-0.88 
            
Type of Exclusive Treatment           
  Estrogen 256 0.81 0.70-0.93 0.88 0.76-1.01 102 1.18 0.94-1.48 124 0.87 0.71-1.07 
  EP 95 0.63 0.51-0.78 0.71 0.57-0.88 37 0.99 0.69-1.43 44 0.63 0.45-0.87 
  Other/Unknown 77 0.90 0.72-1.14 0.99 0.79-1.26 26 1.17 0.78-1.75 37 0.89 0.63-1.26 
            
Former or Current Use by Type of Treatment         
  Estrogen, Former  107 0.81 0.66-0.98 0.86 0.70-1.05 43 1.09 0.79-1.51 56 0.97 0.73-1.28 
  Estrogen, Current 149 0.81 0.68-0.96 0.89 0.74-1.06 59 1.30 0.97-1.74 68 0.79 0.61-1.02 
  EP, Former 20 0.94 0.60-1.46 0.98 0.63-1.53 5 0.81 0.33-1.98 11 1.03 0.56-1.90 
  EP, Current 75 0.57 0.45-0.73 0.65 0.51-0.84 32 1.09 0.73-1.62 33 0.53 0.37-0.78 
            
Duration by Type of Treatment           
  Estrogen, < 5 years 108 0.85 0.70-1.03 0.90 0.73-1.10 43 1.23 0.89-1.70 53 0.86 0.65-1.15 
  Estrogen, ≥ 5 years 148 0.78 0.65-0.92 0.86 0.72-1.03 59 1.17 0.87-1.56 71 0.86 0.67-1.11 
  EP, < 5 years 61 0.75 0.58-0.98 0.84 0.65-1.10 22 1.13 0.72-1.77 30 0.73 0.49-1.07 
  EP, ≥ 5 years 34 0.47 0.33-0.67 0.54 0.38-0.76 15 0.89 0.52-1.53 14 0.46 0.27-0.81 
            
* Proportional hazards models stratified on state, year of interview, and age at diagnosis. 
† Proportional hazards models adjusted for body mass index, menopausal status mammography, and time from date of diagnosis to interview mammography, 
and time from date of diagnosis to interview 
‡ Reference category. 
** Excludes never users 
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TABLE 3. All-cause mortality of women with incident breast cancer by patterns of use of hormone therapy prior to 
diagnosis.  
 
        
Hormone Therapy 
Number of 
Deaths   Rate ratio* (95%CI)   
Multivariate 
rate ratio*†  (95%CI) 
        
Never‡ 2794  1.00 reference  1.00 reference 
Any HT Use 859  0.74 0.69-0.80  0.79 0.73-0.86 
  Former HT Use 402  0.82 0.74-0.91  0.86 0.78-0.96 
  Current HT Use 456  0.68 0.61-0.75  0.73 0.66-0.81 
        
Type of Exclusive Treatment        
  Estrogen Only 561  0.76 0.69-0.83  0.81 0.74-0.89 
  EP 151  0.61 0.51-0.72  0.65 0.55-0.77 
  Other/Unknown 147  0.83 0.70-0.98  0.88 0.74-1.04 
        
Former or Current Use by Type of Treatment       
  Estrogen, Former  290  0.79 0.70-0.90  0.84 0.75-0.95 
  Estrogen, Current 271  0.73 0.64-0.83  0.78 0.69-0.89 
  EP, Former 39  0.93 0.68-1.28  0.96 0.70-1.32 
  EP, Current 112  0.53 0.44-0.65  0.57 0.47-0.70 
        
Duration by Type of Treatment       
  Estrogen, < 5 years 233  0.78 0.69-0.90  0.82 0.72-0.94 
  Estrogen, ≥ 5 years 328  0.75 0.66-0.84  0.81 0.72-0.91 
  EP, < 5 years 94  0.73 0.59-0.91  0.78 0.63-0.97 
  EP, ≥ 5 years 57  0.47 0.36-0.61  0.50 0.38-0.66 
                
* Proportional hazards models stratified on state, year of interview, and age at diagnosis. 
† Proportional hazards models adjusted for body mass index, mammography, and time from date of diagnosis to interview. 
‡ Reference category.        
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FIGURE 1.  Kaplan-meier cumulative incidence of breast cancer mortality according to history of hormone 
use. 
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FIGURE 2.  Kaplan-meier cumulative incidence of breast cancer mortality by type of hormone therapy 
preparation. 
 
 
 
 
 
 
 
 
 
 
 
